Final FDA Approval Received

Aurolife Pharma, LLC, the U.S.-based manufacturing subsidiary of Aurobindo Pharma Limited, a global pharmaceutical company based in India, has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA 203502) for Methadone Hydrochloride Tablets, a μ-Opioid Receptor agonist. This formulation acts on the μ-opioid receptors in the central nervous system, providing potent analgesic effects. It is widely prescribed for managing severe pain and as an adjunct therapy in Medication-Assisted Treatment (MAT) for patients with opioid use disorder. This approval signifies that the product meets the stringent quality standards of the U.S. regulatory authorities, demonstrating bioequivalence to the original drug and securing market access, which holds significant commercial value.

Rapid Growth and Opportunities in the Opioid Treatment Market

Globally, including in the U.S., the market for opioid use disorder treatment is rapidly expanding, projected to reach approximately $4.26 billion to $6.56 billion by 2026. This rapid growth is driven by increased financial support from state and federal governments to improve access to medication-based treatment, aiming to address the opioid abuse crisis in the U.S. Aurolife Pharma is well-positioned to capitalize on this growing demand by flexibly responding to the surge in local market needs, increasing the potential for supplying to public procurement markets and specialized addiction treatment centers, thereby creating opportunities for additional revenue.

Comparison and Positioning with Key Competing Treatments

Currently, the global addiction treatment market is dominated by high-priced branded drugs, such as buprenorphine and naltrexone. However, methadone hydrochloride formulations remain a core standard of care due to their excellent patient compliance and proven long-term clinical safety. Aurolife Pharma's generic drug offers a significant cost advantage over competing drugs, reducing barriers to prescription and is expected to rapidly replace the originator market.

Securing Supply Stability Through Local Production

To address the instability of overseas pharmaceutical distribution networks and meet the U.S. government's preference for domestic production, Aurobindo Pharma has established its U.S. subsidiary, Aurolife Pharma, located in New Jersey, as a key manufacturing base. Given that methadone is a controlled substance, strict management of the distribution network is essential. Local manufacturing helps reduce logistical risks and enhance quality reliability. Moving forward, the company plans to leverage the cost competitiveness of its Indian headquarters and the geographical advantages of its U.S. facility to ensure a stable product supply and strengthen its market position.